Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

7,025 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Assays for proteasome inhibition.
Elliott PJ, Soucy TA, Pien CS, Adams J, Lightcap ES. Elliott PJ, et al. Among authors: adams j. Methods Mol Med. 2003;85:163-72. doi: 10.1385/1-59259-380-1:163. Methods Mol Med. 2003. PMID: 12710207 Review. No abstract available.
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D, Zelenetz AD. O'Connor OA, et al. Among authors: adams j. J Clin Oncol. 2005 Feb 1;23(4):676-84. doi: 10.1200/JCO.2005.02.050. Epub 2004 Dec 21. J Clin Oncol. 2005. PMID: 15613699 Clinical Trial.
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.
Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA, Soignet SL. Orlowski RZ, et al. Among authors: adams j. J Clin Oncol. 2002 Nov 15;20(22):4420-7. doi: 10.1200/JCO.2002.01.133. J Clin Oncol. 2002. PMID: 12431963 Clinical Trial.
7,025 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page